Bio

Gorav Jindal is a skilled antitrust lawyer with hands-on knowledge of agency practice, procedure and personnel. He combines the quantitative analysis of a background in engineering and economics with the persuasive skills of a litigator and nationally ranked intercollegiate debater. He guides clients past antitrust obstacles, providing creative and innovative antitrust analyses, whether in defense of a potential or consummated transaction or as a counselor on the full range of business practices. His work led to his appointment as co-chair of the firm’s Innovation Committee. Gorav’s practice combines government and private sector experience on behalf of clients in a variety of industries. He handles all phases of merger investigations conducted by the U.S. Department of Justice (DOJ) and the FTC. He has navigated clients through the antitrust aspects of transformative transactions and antitrust litigation, and was a vital member of the team that won Global Competition Review’s antitrust “Matter of the Year” award in 2014. He focuses in particular on the pharmaceutical and energy industries and has represented large and small pharmaceutical companies under investigation by the FTC for price-fixing, improperly listing patents in the Orange Book, and entering into illegal patent settlements, as well as allegations of business practices designed to unfairly lengthen the life-cycle of branded drugs under the Hatch-Waxman Act. In 2017, Legal 500 US noted his “particular expertise in antitrust issues connected with the pharmaceuticals sector.” Gorav also has experience in handling antitrust litigation matters. He has assisted in the development of litigation strategy for preliminary injunction hearings and complex commercial litigation. He represents clients that have been targeted in criminal antitrust proceedings, focusing on the plausibility of criminal theories and assessing the likelihood of indictments and convictions. Prior to joining private practice, Gorav served in the FTC’s Bureau of Competition. He investigated a number of highly publicized transactions, including mergers in the publishing, computer hardware and chemical industries.